---
title: "Germany's GKV-BStabG Reform: What It Really Means for Pharma"
description: The GKV-BStabG reform is moving quickly. We've put together a full analysis to help P&MA teams cut through the noise.
image: https://offers.accessinfinity.com/hubfs/DE%20reform%20icon.png
---

[![AI Logo White](https://offers.accessinfinity.com/hs-fs/hubfs/AI%20Logo%20White.png?width=628&height=72&name=AI%20Logo%20White.png "AI Logo White")](https://accessinfinity.com/)

Inside Germany’s Evolving Access Landscape

# Germany's GKV-BStabG Reform: What It Really Means for Pharma

![DE reform icon](https://offers.accessinfinity.com/hs-fs/hubfs/DE%20reform%20icon.png?width=350&height=243&name=DE%20reform%20icon.png "DE reform icon")

### Seven provisions. Two that help industry. Five that do not. This whitepaper provides a structured, provision-by-provision assessment of what was proposed, what is likely to pass, and what your P&MA team must do now.

Why download?

 Understand which provisions are most likely to pass - and how they combine to reshape German market economics  
 Stress-test your revenue assumptions against a range of passage and implementation scenarios  
 Identify whether your portfolio, therapy area, or lifecycle stage faces above-average exposure  
 Equip your leadership team with a structured, evidence-based briefing before the July deadline  
 Gain a clear plan your P&MA team can act on

What's inside?

 Provision-by-provision analysis - Independent assessment of all seven measures in plain language.

 Passage probability - Which provisions will pass as drafted, and which are likely to be narrowed.

 Scenario modelling guidance - Frameworks to stress-test revenue assumptions under different outcomes.

 Most affected companies & therapy areas - Which portfolios and indications face the greatest exposure.

Leadership discussion framework — Structured questions to align cross-functional teams.

 

**This Resource is Essential For:** Global Pricing and Market Access leaders, Launch and Lifecycle Excellence leaders, HEOR and Evidence Strategy leads, who are seeking a structured way to think through the strategic implications of the GKV-BStabG reform. 

### Download the whitepaper

 

## Check out our additional resources

![MA in IRP Feat image Final NEW](https://offers.accessinfinity.com/hs-fs/hubfs/MA%20in%20IRP%20Feat%20image%20Final%20NEW.png?width=1024&height=536&name=MA%20in%20IRP%20Feat%20image%20Final%20NEW.png "MA in IRP Feat image Final NEW")

[Download Part 1 Market Access in the IRP Era](https://offers.accessinfinity.com/navigating-mfn-drug-pricing-reform)<https://accessinfinity.com/webinar/winning-the-launch-game-layering-competitor-intelligence-into-your-strategy-with-access-hub/>

![Analogue analysis blog scorecard](https://offers.accessinfinity.com/hs-fs/hubfs/Analogue%20analysis%20blog%20scorecard.png?width=1024&height=536&name=Analogue%20analysis%20blog%20scorecard.png "Analogue analysis blog scorecard")

[Read Analogue Analysis in Rare Diseases](https://accessinfinity.com/blogs/analogue-analysis-in-rare-diseases/)<https://offers.accessinfinity.com/market-access-kpi>

![W19 On demand Access Now Feat image](https://offers.accessinfinity.com/hs-fs/hubfs/W19%20On%20demand%20Access%20Now%20Feat%20image.png?width=1024&height=536&name=W19%20On%20demand%20Access%20Now%20Feat%20image.png "W19 On demand Access Now Feat image")

[Watch 'AI in market access: Smart applications and limitations'](https://offers.accessinfinity.com/ai-in-market-access-webinar-series)

Copyright © 2026 Access Infinity. All Rights Reserved.